AAAAAA
Results:
1-21
|
Results: 21
Authors:
Waterhouse, DN
Dos Santos, N
Mayer, LD
Bally, MB
Citation: Dn. Waterhouse et al., Drug-drug interactions arising from the use of liposomal vincristine in combination with other anticancer drugs, PHARM RES, 18(9), 2001, pp. 1331-1335
Visualization of bioavailable liposomal doxorubicin using a non-perturbingconfocal imaging technique
Authors:
Krishna, R
Ghiu, G
Mayer, LD
Citation: R. Krishna et al., Visualization of bioavailable liposomal doxorubicin using a non-perturbingconfocal imaging technique, HIST HISTOP, 16(3), 2001, pp. 693-699
Authors:
Krishna, R
Webb, MS
St Onge, G
Mayer, LD
Citation: R. Krishna et al., Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties, J PHARM EXP, 298(3), 2001, pp. 1206-1212
Authors:
Li, WM
Xue, L
Mayer, LD
Bally, MB
Citation: Wm. Li et al., Intermembrane transfer of polyethylene glycol-modified phosphatidylethanolamine as a means to reveal surface-associated binding ligands on liposomes, BBA-BIOMEMB, 1513(2), 2001, pp. 193-206
Authors:
Chiu, GNC
Bally, MB
Mayer, LD
Citation: Gnc. Chiu et al., Selective protein interactions with phosphatidylserine containing liposomes alter the steric stabilization properties of poly(ethylene glycol), BBA-BIOMEMB, 1510(1-2), 2001, pp. 56-69
Authors:
de Menezes, DEL
Hudon, N
McIintosh, N
Mayer, LD
Citation: Del. De Menezes et al., Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin, CLIN CANC R, 6(7), 2000, pp. 2891-2902
Authors:
Krishna, R
Mayer, LD
Citation: R. Krishna et Ld. Mayer, Multidrug resistance (MDR) in cancer - Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, EUR J PH SC, 11(4), 2000, pp. 265-283
Authors:
Webb, MS
Sarris, AH
Cabanillas, F
Mayer, LD
Bally, MB
Burge, C
Cullis, PR
Citation: Ms. Webb et al., Clinical and preclinical pharmacology of liposomal vincristine, J LIPOS RES, 10(4), 2000, pp. 501-512
Authors:
Mayer, LD
Krishna, R
Webb, M
Bally, M
Citation: Ld. Mayer et al., Designing liposomal anticancer drug formulations for specific therapeutic applications, J LIPOS RES, 10(2-3), 2000, pp. 99-115
Authors:
Johnstone, SA
Gelmon, K
Mayer, LD
Hancock, RE
Bally, MB
Citation: Sa. Johnstone et al., In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines, ANTI-CAN DR, 15(2), 2000, pp. 151-160
Authors:
Dragowska, WH
de Menezes, DEL
Sartor, J
Mayer, LD
Citation: Wh. Dragowska et al., Quantitative fluorescence cytometric analysis of Bcl-2 levels in tumor cells exhibiting a wide range of inherent Bcl-2 protein expression: Correlation with Western blot analysis, CYTOMETRY, 40(4), 2000, pp. 346-352
Authors:
Chi, KN
Wallis, AE
Lee, CH
de Menezes, DL
Sartor, J
Dragowska, WH
Mayer, LD
Citation: Kn. Chi et al., Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression, BREAST CANC, 63(3), 2000, pp. 199-212
Authors:
Krishna, R
St-Louis, M
Mayer, LD
Citation: R. Krishna et al., Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar (psc 833) with sterically stabilized liposomal doxorubicin, INT J CANC, 85(1), 2000, pp. 131-141
Authors:
Newman, MJ
Rodarte, JC
Benbatoul, KD
Romano, SJ
Zhang, CZ
Krane, S
Moran, EJ
Uyeda, RT
Dixon, R
Guns, ES
Mayer, LD
Citation: Mj. Newman et al., Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance, CANCER RES, 60(11), 2000, pp. 2964-2972
Authors:
Zhang, LJ
Scott, MG
Yan, H
Mayer, LD
Hancock, REW
Citation: Lj. Zhang et al., Interaction of polyphemusin I and structural analogs with bacterial membranes, lipopolysaccharide, and lipid monolayers, BIOCHEM, 39(47), 2000, pp. 14504-14514
Authors:
Krishna, R
McIntosh, N
Riggs, KW
Mayer, LD
Citation: R. Krishna et al., Doxorubicin encapsulated in sterically stabilized liposomes exhibits renaland biliary clearance properties that are independent of valspodar (PSC 833) under conditions that significantly inhibit nonencapsulated drug excretion, CLIN CANC R, 5(10), 1999, pp. 2939-2947
Authors:
Saxon, DN
Mayer, LD
Bally, MB
Citation: Dn. Saxon et al., Liposomal anticancer drugs as agents to be used in combination with other anticancer agents: Studies on a liposomal formulation with two encapsulateddrugs, J LIPOS RES, 9(4), 1999, pp. 507-522
Authors:
Gelmon, KA
Tolcher, A
Diab, AR
Bally, MB
Embree, L
Hudon, N
Dedhar, C
Ayers, D
Eisen, A
Melosky, B
Burge, C
Logan, P
Mayer, LD
Citation: Ka. Gelmon et al., Phase I study of liposomal vincristine, J CL ONCOL, 17(2), 1999, pp. 697-705
Authors:
Krishna, R
Mayer, LD
Citation: R. Krishna et Ld. Mayer, The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR), ANTICANC R, 19(4B), 1999, pp. 2885-2891
Authors:
Mayer, LD
Reamer, J
Bally, MB
Citation: Ld. Mayer et al., Intravenous pretreatment with empty pH gradient liposomes alters the pharmacokinetics and toxicity of doxorubicin through in vivo active drug encapsulation, J PHARM SCI, 88(1), 1999, pp. 96-102
Authors:
Mayer, LD
Cullis, PR
Bally, MB
Citation: Ld. Mayer et al., Designing therapeutically optimized liposomal anticancer delivery systems:Lessons from conventional liposomes, MEDICAL APPLICATIONS OF LIPOSOMES, 1998, pp. 231-257
Risultati:
1-21
|